Importantly, targeting this metabolism, either with a specific agent (tigecycline) or a SIRT1 knockout led to the impairment of CML stem cell functions, showing synergistic interaction with tyrosine kinase inhibitors [80,81]. The gene discussed is SIRT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.